| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.7M | +71.0% |
| SG&A Expense | $6.6M | +46.3% |
| Net Income | -$9.4M | +56.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.9M | -61.8% |
| Current Assets | $13.4M | +57.3% |
| Total Assets | $14.5M | +54.5% |
| Current Liabilities | $3.5M | -22.9% |
| Total Liabilities | $7.1M | -18.9% |
| Stockholders' Equity | $7.4M | +1027.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.5M | -48.3% |
| Investing Cash Flow | -$10.1M | -1523.9% |
| Financing Cash Flow | $14.0M | +3.7% |